Betamethasone
FDA-approved product (tablet, oral), marketed as Celestone.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Eye inflammation
- Hemorrhoid
- Nasal congestion
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Corticosteroids acting locally; Corticosteroids; Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Betamethasone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis
NCT07635043 · start 2026-08-01
Registered record
- Registry ID
- NCT07635043
- Conditions
- Psoriasis (PsO)
- Interventions
- Betamethasone Dipropionate 0.05% Cream; Tapinarof Cream 1%
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Not yet recruiting
- Start
- 2026-08-01
- Completion
- 2026-11-30
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsoriasis (PsO)InterventionBetamethasone Dipropionate 0.05% Cream; Tapinarof Cream 1%PhasePhase 4Registry statusNot yet recruitingClinical and Economic Evaluation of Point-of-care Ultrasound-guided Infiltration for Subacromial and Carpal Tunnel Syndromes in Primary Care: a Cluster-randomized Study Protocol.
NCT07692516 · start 2026-06-01
Registered record
- Registry ID
- NCT07692516
- Conditions
- Subacromial Impingement Syndrome; Carpal Tunnel Syndrome (CTS); Pain Management
- Interventions
- Standard Oral Treatment; Conventional Infiltration; Ultrasound-Guided Infiltration
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Active not recruiting
- Start
- 2026-06-01
- Completion
- 2028-06-30
- Enrolment
- 225
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSubacromial Impingement Syndrome; Carpal Tunnel Syndrome (CTS); Pain ManagementInterventionStandard Oral Treatment; Conventional Infiltration; Ultrasound-Guided InfiltrationPhasePhase 4Registry statusActive not recruitingCan Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?
NCT07447739 · start 2026-04
Registered record
- Registry ID
- NCT07447739
- Conditions
- Respiratory Distress Syndrome (RDS); Bronchopulmonary Dysplasia (BPD)
- Interventions
- Betamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-04
- Completion
- 2029-03
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRespiratory Distress Syndrome (RDS); Bronchopulmonary Dysplasia (BPD)InterventionBetamethasonePhasePhase 2Registry statusNot yet recruitingA Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
NCT07453004 · start 2026-03-26
Registered record
- Registry ID
- NCT07453004
- Conditions
- Acute Gouty Arthritis
- Interventions
- Plonmarlimab; Compound betamethasone; Plonmarlimab placebo; Compound betamethasone placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-03-26
- Completion
- 2027-12-31
- Enrolment
- 170
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Gouty ArthritisInterventionPlonmarlimab; Compound betamethasone; Plonmarlimab placebo; Compound betamethasone placeboPhasePhase 2Registry statusRecruitingComparison of Efficacy of Betamethasone Gel With Lidocaine Gel in Prevention of Post Endotracheal Intubation Sore Throat.
NCT07256834 · start 2025-11-22
Registered record
- Registry ID
- NCT07256834
- Conditions
- Post Operative Sore Throat at 6hrs and 24hrs After Endotracheal Intubation
- Interventions
- Betamethasone dipropionate 0.05%; Lidocaine hydrochloride 2%
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Not yet recruiting
- Start
- 2025-11-22
- Completion
- 2025-12-06
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost Operative Sore Throat at 6hrs and 24hrs After Endotracheal IntubationInterventionBetamethasone dipropionate 0.05%; Lidocaine hydrochloride 2%PhasePhase 1 / Phase 2Registry statusNot yet recruitingMeniscal INfiltration of Corticosteroid Guided With Ultra Sonography
NCT06527235 · start 2025-03-06
Registered record
- Registry ID
- NCT06527235
- Conditions
- Meniscus Lesion
- Interventions
- ultrasound-guided betamethasone infiltration of the meniscal wall; ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2025-03-06
- Completion
- 2028-06-01
- Enrolment
- 152
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMeniscus LesionInterventionultrasound-guided betamethasone infiltration of the meniscal wall; ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wallPhasePhase 3Registry statusRecruitingSuprascapular Nerve Block in the Management of Patients Diagnosed With Adhesive Capsulitis
NCT07097571 · start 2025-02-26
Registered record
- Registry ID
- NCT07097571
- Conditions
- Adhesive Capsulitis of the Shoulder; Suprascapular Nerve Block
- Interventions
- Glenohumeral Joint Injection and Suprascapular Nerve Block
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Active not recruiting
- Start
- 2025-02-26
- Completion
- 2026-08-26
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdhesive Capsulitis of the Shoulder; Suprascapular Nerve BlockInterventionGlenohumeral Joint Injection and Suprascapular Nerve BlockPhaseNot applicableRegistry statusActive not recruitingAnalgesic Efficacy of Preemptive Stepwise Infiltration Anesthesia for Perioperative Analgesia After TKA
NCT06600815 · start 2024-09-30
Registered record
- Registry ID
- NCT06600815
- Conditions
- Total Knee Arthroplasty; Pain Management
- Interventions
- preemptive stepwise infiltration anaesthesia(PSIA); postoperative local infiltration analgesia(PLIA)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2024-09-30
- Completion
- 2025-12
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTotal Knee Arthroplasty; Pain ManagementInterventionpreemptive stepwise infiltration anaesthesia(PSIA); postoperative local infiltration analgesia(PLIA)PhaseNot applicableRegistry statusRecruitingEffect of Corticosteroid Injection in Symptomatic Pulpitis Cases
NCT07704398 · start 2023-10-23
Registered record
- Registry ID
- NCT07704398
- Conditions
- Periapical Periodontitis
- Interventions
- Corticosteroid; Standard endodontic treatment
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-10-23
- Completion
- 2026-04-23
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPeriapical PeriodontitisInterventionCorticosteroid; Standard endodontic treatmentPhaseNot applicableRegistry statusCompletedThe Effects of Two Different Treatment Protocols on Shoulder Function, Quality of Life, and Ultrasound Parameters in Patients With Frozen Shoulder
NCT05956171 · start 2023-10-01
Registered record
- Registry ID
- NCT05956171
- Conditions
- Frozen Shoulder; Shoulder Capsulitis; Shoulder Pain
- Interventions
- Intra-articular corticosteroid injection; Ultrasound Guided Hydrodilatation with corticosteroid injection
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2023-10-01
- Completion
- 2024-03
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFrozen Shoulder; Shoulder Capsulitis; Shoulder PainInterventionIntra-articular corticosteroid injection; Ultrasound Guided Hydrodilatation with corticosteroid injectionPhaseNot applicableRegistry statusUnknownEfficacy and Safety of Timolol for TKI Induced Paronychia
NCT06140186 · start 2023-04-01
Registered record
- Registry ID
- NCT06140186
- Conditions
- Paronychia
- Interventions
- Topical Timolol; Betamethasone Valerate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2023-04-01
- Completion
- 2024-03-31
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParonychiaInterventionTopical Timolol; Betamethasone ValeratePhasePhase 3Registry statusUnknownEfficacies of Different Managements in Patients With Trigger Finger
NCT06382623 · start 2022-10-01
Registered record
- Registry ID
- NCT06382623
- Conditions
- Trigger Finger
- Interventions
- The percutaneous A1 pulley release; The peritendinous Betamethasone group
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2022-10-01
- Completion
- 2023-06-30
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTrigger FingerInterventionThe percutaneous A1 pulley release; The peritendinous Betamethasone groupPhaseNot recordedRegistry statusCompletedComparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects
NCT05531890 · start 2022-09-13
Registered record
- Registry ID
- NCT05531890
- Conditions
- Ataxia Telangiectasia
- Interventions
- GTX-102 medium dose fast Period 1 and Period 2; GTX-102 medium dose slow Period 1 and Period 2; GTX-102 high dose fast Period 1 and Period 2; GTX-102 low dose fast Period 1 and Period 2; Betamethasone solution as intramuscular injection Period 1 and Period 2; Betamethasone Oral Solution Period 1 and Period 2
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2022-09-13
- Completion
- 2023-05-03
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtaxia TelangiectasiaInterventionGTX-102 medium dose fast Period 1 and Period 2; GTX-102 medium dose slow Period 1 and Period 2; GTX-102 high dose fast Period 1 and Period 2; GTX-102 low dose fast Period 1 and Period 2 +2 morePhasePhase 1Registry statusUnknownTopical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis
NCT06011083 · start 2022-08-01
Registered record
- Registry ID
- NCT06011083
- Conditions
- Psoriasis Vulgaris; Fractional CO2 Laser
- Interventions
- Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm; Fractional carbon dioxide (CO2) laser
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-08-01
- Completion
- 2023-08-01
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsoriasis Vulgaris; Fractional CO2 LaserInterventionTopical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm; Fractional carbon dioxide (CO2) laserPhaseNot applicableRegistry statusCompletedEfficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Intercostal Nerve Block for Chronic Post-thoracotomy Pain
NCT05556122 · start 2022-07-04
Registered record
- Registry ID
- NCT05556122
- Conditions
- Nerve Block
- Interventions
- intercostal nerve block; lateral intercostal nerve block; ropivacaine + compound betamethasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2022-07-04
- Completion
- 2022-12-30
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNerve BlockInterventionintercostal nerve block; lateral intercostal nerve block; ropivacaine + compound betamethasonePhaseNot applicableRegistry statusUnknown